Electromed (NSDQ:ELMD) CEO Robert Hansen said the company expects its sales and earnings numbers to slide for the 2nd quarter and 2nd half of 2012, after a sales force restructuring hit its top line.
HeartWare International Inc.
Heartware and Dualis team up on wireless VAD
HeartWare International (NSDQ:HTWR) and Dualis MedTech GmbH are teaming up to develop a wireless left ventricular assist device, in a deal that could help the Framingham, Mass.-based cardiac device maker expand its product portfolio.
Company officials said engineering teams from Dualis and HeartWare have been working together since mid-2011 and have, “successfully demonstrated the feasibility of integrating Dualis’ proprietary wireless energy transfer technology with the HeartWare HVAD and MVAD systems,” according to a prepared release.
Welch Allyn CEO Julie Shimer to retire | Personnel Moves
Welch Allyn president & CEO Julie Shimer announced plans to retire from the Skaneateles Falls, N.Y.-based diagnostics maker by the end of 2012.
Shimer became the first woman to hold the corner office at the 95-year old company when she took the position in 2007 after 5 years on the med-tech maker’s board of directors.
Abiomed hits 52-week high | Wall Street Beat
Abiomed (NSDQ:ABMD) shares hit $20.25 apiece yesterday, their highest mark in 52 weeks, as the company touted more positive study results for its flagship Impella heart pump.
ABMD shares closed yesterday at $20.14, up 6.2 percent on a day of widespread gains on Wall Street. The Dow Jones Industrial Average gained 4.2 percent yesterday, the S&P 500 closed up 4.3 percent and the Dow Jones medical device index rose 4.8 percent.
HeartWare’s Q3 sales rise, losses widen; CFO to step down | Earnings Roundup
HeartWare International (NSDQ:HTWR) posted record revenues of $21.3 million during the third quarter, up 54.4 percent, but saw losses gap wider by a whopping 78 percent.
The Framingham, Mass.-based medical device maker also said CFO David McIntyre is stepping down to move back to Australia to rejoin family.
HeartWare posted a net loss of $14.0 million, or $1.00 per share, for the three months ended Sept. 30. That compares with losses of $7.8 million, or 57 cents per share, on sales of $13.8 million during the same period last year.
HeartWare’s Q3 sales rise, losses widen; CFO to step down
HeartWare International (NSDQ:HTWR) posted record revenues of $21.3 million during the third quarter, up 54.4 percent, but saw losses gap wider by a whopping 78 percent.
The Framingham, Mass.-based medical device maker also said CFO David McIntyre is stepping down to move back to Australia to rejoin family.
HeartWare posted a net loss of $14.0 million, or $1.00 per share, for the three months ended Sept. 30. That compares with losses of $7.8 million, or 57 cents per share, on sales of $13.8 million during the same period last year.
Early-stage angel investment rises, but early-stage VC funding falls
Venture capital investment is on the wane, but angel investment is increasing, according to a pair of recent reports.
The University of New Hampshire’s Center for Venture Research reports that angel investment rose nearly 5 percent during the first and second quarters, to $8.9 billion, compared with the same period last year. Health care and medical device firms took the lion’s share of the angel cash (25 percent, according to the report), which usually comes from the proverbial "high net worth individuals" or in early-stage funding rounds.
HeartWare jumps on bridge-to-transplant study results
Shares of HeartWare International Inc. (NSDQ:HTWR) rose nearly 5 percent today after an update on a bridge-to-transplant trial of its implantable heart pump showed 93 percent of the 241 patients survived for at least six months after receiving the device.
The Framingham, Mass.-based firm presented the results from the Advance BTT study and its continued access protocol arm at the European Assn. for Cardio-Thoracic Surgery’s annual meeting in Lisbon.
Is J&J in the hunt for Boston Scientific?
Could the amicable deal between bitter rivals Johnson & Johnson (NYSE:JNJ) and Boston Scientific (NYSE:BSX) over Michael Mahoney leaving J&J to helm BSX signal an upcoming acquisition?
Opinions are divided on Wall Street, with at least one analyst wondering if a deal could be in the works and others casting doubt on the speculation.
HeartWare notches reimbursement win in France
HeartWare International Inc. (NSDQ:HTWR) won full reimbursement from the French government with publication in an official journal there.
That means French heart patients implanted with the Framingham, Mass.-based company’s ventricular assist device will be covered by that country’s national health care system effective July 4, according to a regulatory filing.
Abiomed, Thoratec and Heartware listed as potential buyout candidates by UBS
Abiomed Inc.’s (NSDQ:ABMD recent good fortune may make it a prime acquisition target, according to Wall Street analysts.